Nasdaq
$223.37▼ 0.27%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $29.82BShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.6After-hours26.10.07 05:124Ownership#●●●
ALNYLAM PHARMACEUTICALS, INC.
Alnylam Pharmaceuticals, Inc. executive Bryan Supran filed a Form 4 report regarding changes in beneficial ownership of securities as of October 2, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$223.37-0.27%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2Regular26.10.03 04:45144Ownership
ALNYLAM PHARMACEUTICALS, INC.
Alnylam Pharmaceuticals insider Supran Bryan has filed Form 144 to report a proposed sale of company securities. This is a standard regulatory filing regarding the planned disposal of shares by an insider.…more
$223.37-0.27%vs prev closeView filingShare - 9.22After-hours26.09.23 05:074Ownership
ALNYLAM PHARMACEUTICALS, INC.
Yvonne Greenstreet, an executive at Alnylam Pharmaceuticals, reported a change in beneficial ownership of company securities on September 19, 2026. This filing serves as a standard Form 4 disclosure regarding insider stock holdings.…more
$223.37-0.27%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoOvernight26.10.23 16:46#●●●#●●●#●●●
Alnylam Reports Positive Phase 1b Results for Huntington’s Drug Brezosiran…more
Alnylam's experimental drug Brezosiran showed up to 83% reduction in mutant huntingtin protein in a Phase 1b study with a favorable safety profile. The company plans to initiate a pivotal study in 2027, subject to regulatory alignment.…more
$223.37-0.27%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.31Overnight26.08.31 16:43
●●●●●●●● ●●●●● ●●●●●●
Alnylam Pharmaceuticals presented new data at the ESC Congress reinforcing the clinical profile of AMVUTTRA and the potential of its RNAi platform for treating uncontrolled hypertension. While the findings highlight the company's R&D progress, they represent ongoing clinical research rather than immediate commercial milestones.…more
$223.37-0.27%vs prev closeShareBenzinga - 8.24Pre-market26.08.24 21:35
●●●●●●●● ●●●●● ●●●●●●
Alnylam Pharmaceuticals will present new clinical and real-world data for its ATTR amyloidosis and hypertension programs at the upcoming ESC Congress 2026. The presentations aim to highlight the efficacy of its RNAi-based therapies, AMVUTTRA and zilebesiran.…more
$223.37-0.27%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report